Serina Therapeutics
Serina Therapeutics' revenue rose 132.1% to $0 million in fiscal 2025. Its operating margin was −18,478.5%, up from −30,442.9% a year earlier. Free cash flow was −$18 million. The diluted share count rose 38.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Serina Therapeutics lost money in fiscal 2025: a net loss of $19 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1 | 1 | 8 | 4 | 3 |
| Debt incl. finance leases | 13 | 18 | 3 | 0 | 3 |
| Net debt (negative means net cash) | 13 | 18 | −5 | −4 | −0 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.0x | — |
| Interest coverage | −7.2x | −2.1x | −0.6x | −32.4x | −112.8x |
| Current ratio | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Quick ratio | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
Cash flow
Projections
Project Serina Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $77,955 of Serina Therapeutics shares on the open market, and 1 insider sold $335,128, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Stephen K. BrannanDirector | Bought | 1,000 | $2.03 | $2,030 | Form 4 |
| Jun 12, 2026 | Karen J WilsonDirector | Bought | 5,000 | $1.77 | $8,850 | Form 4 |
| Jun 11, 2026 | Karen J WilsonDirector | Bought | 5,100 | $1.75 | $8,925 | Form 4 |
| May 22, 2026 | Karen J WilsonDirector | Bought | 10,000 | $1.93 | $19,300 | Form 4 |
| May 22, 2026 | Jay VenkatesanDirector | Bought | 589 | $1.78 | $1,048 | Form 4 |
| May 21, 2026 | Karen J WilsonDirector | Bought | 10,000 | $1.77 | $17,700 | Form 4 |
| May 19, 2026 | Richard Peter MarshallDirector | Bought | 12,183 | $1.65 | $20,102 | Form 4 |
| Mar 23, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $2.86 | $18,590 | Form 4 |
| Mar 19, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 39,000 | $2.50 | $97,500 | Form 4 |
| Feb 2, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $3.03 | $19,695 | Form 4 |
| Jan 28, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $3.57 | $23,205 | Form 4 |
| Jan 22, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 2,500 | $2.95 | $7,375 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 1 of 8 | 2 of 8 |
| Rule of 40 | 9,079.0% | −30,739.3% | −13,724.8% |
| Altman Z'' | −16.85 | −35.21 | −50.64 |
| Accruals ratio | 126.9% | 76.4% | −17.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 9 | 1 of 8 | 2 of 8 |
Compare
Put Serina Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Serina Therapeutics | FY25 | 132.1% | −18,478.5% | −13,856.9% | — | — | 2 | |
| Actinium Pharmaceuticals | FY25 | — | −40,274.4% | −27,426.7% | — | — | — | Compare |
| Avalo Therapeutics | FY25 | −86.6% | −123,601.7% | — | — | — | 2 | Compare |
| iBio | FY26 | −75.0% | −35,141.0% | −23,796.0% | — | — | — | Compare |
| Inovio Pharmaceuticals | FY25 | −70.0% | −132,871.3% | −136,074.5% | — | — | 0 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 0 |
| Revenue growth | — | −0.6% | 23.8% | −79.1% | −60.1% | −76.4% | 9,173.5% | −98.2% | 132.1% |
| Gross profit | 1 | 1 | 2 | 0 | 0 | 0 | 0 | — | — |
| Research and development | 6 | 6 | 6 | 4 | 2 | 1 | 2 | 8 | 13 |
| Operating income | −7 | −11 | −13 | −10 | −8 | −7 | −3 | −17 | −24 |
| Net income | −7 | −8 | −12 | −11 | −9 | −10 | 5 | −11 | −19 |
| Diluted EPS (US$) | −0.21 | −0.21 | −0.33 | — | — | −9.70 | 0.73 | −1.51 | −1.91 |
| Diluted shares (millions) | 31 | 35 | 37 | 38 | 38 | 1 | 7 | 7 | 10 |
| Cash flow | |||||||||
| Cash from operations | −6 | −8 | −10 | −8 | −8 | −6 | −2 | −17 | −18 |
| Capital expenditure | 0 | 0 | 1 | 0 | — | — | 0 | 0 | 0 |
| Free cash flow | −6 | −8 | −11 | −8 | — | — | −3 | −17 | −18 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 3 | 4 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 7 | 7 | 2 | 0 | 1 | 1 | 8 | 4 | 3 |
| Debt incl. finance leases | — | — | — | — | 13 | 18 | 3 | 0 | 3 |
| Total assets | 10 | 11 | 7 | 4 | 3 | 3 | 9 | 7 | 7 |
| Total liabilities | 1 | 2 | 5 | 9 | 15 | 21 | 5 | 6 | 7 |
| Shareholders' equity | 7 | 7 | 2 | −5 | −12 | −17 | −32 | 1 | −0 |
| Margins and ratios | |||||||||
| Gross margin | 88.0% | 73.9% | 85.9% | 92.8% | 86.8% | 61.8% | 3.2% | — | — |
| Operating margin | −474.6% | −805.5% | −726.8% | −2,797.8% | −5,509.0% | −20,514.7% | −99.2% | −30,442.9% | −18,478.5% |
| Net margin | −468.7% | −537.4% | −703.4% | −3,009.7% | −6,024.3% | −30,770.6% | 167.1% | −19,894.6% | −14,755.4% |
| Free cash flow margin | −447.7% | −574.2% | −625.1% | −2,170.9% | — | — | −94.5% | −30,641.1% | −13,856.9% |
| Rule of 40 (growth + FCF margin) | — | −574.8% | −601.3% | −2,250.0% | — | — | 9,079.0% | −30,739.3% | −13,724.8% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −101.9% | −251.5% | — | — | — | — | — | — |
| Return on assets | — | −73.9% | −134.2% | −191.2% | −245.1% | −327.2% | 86.3% | −142.0% | −280.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |